Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Capricor Therapeutics Inc

Healthcare US CAPR

29.34USD
0.96(3.38%)

Last update at 2026-06-22T20:00:00Z

Day Range

28.8930.19
LowHigh

52 Week Range

4.3040.37
LowHigh

Fundamentals

  • Previous Close 28.38
  • Market Cap2044.07M
  • Volume1675820
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-106.25309M
  • Revenue TTM11.13M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM -84.45459M
  • Diluted EPS TTM-2.26

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -105.04395M -40.46719M -22.28754M -29.01953M -20.02252M
Minority interest - - - - -
Net income -105.04395M -40.46719M -22.28754M -29.01885M -19.40911M
Selling general administrative 22.75M 14.87M 12.81M 10.43M 7.61M
Selling and marketing expenses - - 12795.30M - -
Gross profit - -27.69812M -11.26997M 2.55M 0.24M
Reconciled depreciation 1.89M 1.43M 0.95M 0.53M 0.25M
Ebit - -42.56484M -24.07786M -29.69738M -20.93844M
Ebitda -108.14213M -41.13963M -23.00898M -30.18465M -21.30616M
Depreciation and amortization - 1.43M 1.07M -0.48727M -0.36772M
Non operating income net other - - - 0.68M 0.92M
Operating income -108.14213M -42.56484M -24.07786M -29.69738M -20.93844M
Other operating expenses 108.14M 64.84M 49.26M 32.25M 21.18M
Interest expense 3.05M 0.00000M - -1.69757M 1.04M
Tax provision 0.00160M 0.00160M - - -
Interest income - - - - -
Net interest income -3.04573M 0.00000M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M -0.00068M -0.61341M
Total revenue 0.00000M 22.27M 25.18M 2.55M 0.24M
Total operating expenses 108.14M 14.87M 12.81M 32.25M 21.18M
Cost of revenue - 49.97M 36.45M - -
Total other income expense net 3.10M 2.10M 1.79M 0.68M 0.92M
Discontinued operations - - - - -
Net income from continuing ops -105.04395M -40.46719M -29.24637M -29.01953M -20.02252M
Net income applicable to common shares - - - -29.01953M -20.02252M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 355.95M 170.48M 58.73M 50.09M 41.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.75M 1.50M 1.00M 0.92M 1.16M
Total liab 50.16M 25.02M 36.13M 38.31M 9.96M
Total stockholder equity 305.79M 145.46M 22.60M 11.79M 31.37M
Deferred long term liab - - - - -
Other current liab 15.56M 12.01M 6250.24M 0.09M 3.72M
Common stock 0.06M 0.05M 0.03M 0.03M 0.02M
Capital stock 0.06M 0.05M 0.03M 0.03M 0.02M
Retained earnings -304.87849M -199.83454M -159.36735M -137.07981M -108.06028M
Other liab - - - 12.84M 3.38M
Good will - - - - -
Other assets - - - 0.27M 0.28M
Cash 287.85M 11.29M 14.69M 9.60M 34.89M
Cash and equivalents - - - - -
Total current liabilities 35.84M 21.03M 31.27M 23.59M 4.13M
Current deferred revenue 12.00M 12.00M 24.27M 17.98M -
Net debt -266.90256M -9.83588M -9.08270M -7.04313M -32.01494M
Short term debt 6.62M 0.83M 0.75M 0.68M 0.42M
Short long term debt - - - - -
Short long term debt total 20.94M 1.45M 5.61M 2.56M 2.87M
Other stockholder equity 610.33M 344.22M 181.70M 148.74M 139.40M
Property plant equipment - - - 4.59M 4.62M
Total current assets 322.94M 163.39M 50.86M 42.89M 36.44M
Long term investments - - - - -
Net tangible assets - - - 11.79M 36.74M
Short term investments 30.28M 140.23M 24.79M 31.82M -
Net receivables 0.06M 10.37M 10.37M 0.55M 0.39M
Long term debt - - - 3.38M 3.38M
Inventory - - 0.00000M - -
Accounts payable 1.65M 8.18M 6.25M 4.83M 3.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.28M 1.03M 0.24M 0.11M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -137.07981M -108.06028M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.70M 0.22M 0.27M 0.27M 0.28M
Deferred long term asset charges - - - - -
Non current assets total 33.01M 7.10M 7.88M 7.21M 4.89M
Capital lease obligations 14.52M 1.45M 2.24M 2.56M 2.87M
Long term debt total - - - 3.38M 3.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 109.20M -116.18387M 16.11M -31.71278M -1.19629M
Change to liabilities - - - 1.21M 0.99M
Total cashflows from investing activities 97479.28M -116.18387M 5.11M -35.07251M -1.19629M
Net borrowings - - - - -
Total cash from financing activities 248892.30M 152.77M 25.58M 4.87M 20.23M
Change to operating activities - - - 0.25M -0.41708M
Net income -105043.94600M -40.46719M -22.28754M -29.01953M -20.02252M
Change in cash 276560.32M -3.40786M 5.09M -25.28203M 2.22M
Begin period cash flow 11287.00M 14.69M 9.60M 34.89M 32.67M
End period cash flow 287847.31M 11.29M 14.69M 9.60M 34.89M
Total cash from operating activities -69811.26100M -39.99574M -25.59654M 4.92M -16.80932M
Issuance of capital stock 237.03M 152.32M 5.27M 4.80M 20.17M
Depreciation 1889.04M 1.43M 1.07M 0.53M 0.25M
Other cashflows from investing activities -8819.73500M -1.53897M - -1.35949M -
Dividends paid - - - - -
Change to inventory - - - - 391.75M
Change to account receivables 10.31M 0.00350M -9.82441M -0.00016M -391.75000M
Sale purchase of stock - - - 4.87M 20.23M
Other cashflows from financing activities 248643.40M 0.45M 0.06M 0.07M 0.05M
Change to netincome - - - 4.49M 2.79M
Capital expenditures 2904.46M 1.54M 2.05M 3.36M 1.20M
Change receivables - - - -0.15583M -0.39175M
Cash flows other operating - - - 27.86M -0.01510M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -25.28203M 2.22M
Change in working capital 12.20M -10.78448M -11.75204M 28.75M 0.18M
Stock based compensation 16967.80M 9.77M 7.39M 4.46M 2.97M
Other non cash items 16363.65M 0.07M -0.01824M 0.20M 0.13M
Free cash flow -72715.72200M -41.53472M -27.64408M 1.56M -18.00561M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CAPR
Capricor Therapeutics Inc		 0.96 3.38% 29.34 - 78.74 124.43 6.47 141.52 -2.734
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics Inc

10865 Road to the Cure, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Frank Isaac Litvack FACC, M.D. Exec. Chairman 1956
Dr. Linda Marbán Ph.D. Co-Founder, Pres, CEO & Director 1963
Mr. Anthony J. Bergmann M.B.A. CFO & Corp. Treasurer 1986
Ms. Karen G. Krasney Exec. VP, Gen. Counsel & Sec. 1953
Dr. Eduardo Marbán Co-Founder & Chairman of Scientific Advisory Board NA
Mr. Xavier Avat Chief Bus. Officer NA
Dr. Deborah D. Ascheim Consultant 1965
Catherine Lee Kelleher Consultant NA
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 1956
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.